| Online-Ressource |
Verfasst von: | Chiriac, Ute [VerfasserIn]  |
| Richter, Daniel [VerfasserIn]  |
| Frey, Otto R. [VerfasserIn]  |
| Röhr, Anka C. [VerfasserIn]  |
| Helbig, Sophia [VerfasserIn]  |
| Hagel, Stefan [VerfasserIn]  |
| Liebchen, Uwe [VerfasserIn]  |
| Weigand, Markus A. [VerfasserIn]  |
| Brinkmann, Alexander [VerfasserIn]  |
Titel: | Software- and TDM-guided dosing of Meropenem promises high rates of target attainment in critically Ill patients |
Verf.angabe: | Ute Chiriac, Daniel Richter, Otto R. Frey, Anka C. Röhr, Sophia Helbig, Stefan Hagel, Uwe Liebchen, Markus A. Weigand and Alexander Brinkmann |
Jahr: | 2023 |
Umfang: | 14 S. |
Illustrationen: | Illustrationen |
Fussnoten: | Veröffentlicht: 27. Juni 2023 ; Gesehen am 25.08.2023 |
Titel Quelle: | Enthalten in: Antibiotics |
Ort Quelle: | Basel : MDPI, 2012 |
Jahr Quelle: | 2023 |
Band/Heft Quelle: | 12(2023), 7, Artikel-ID 1112, Seite 1-14 |
ISSN Quelle: | 2079-6382 |
Abstract: | Various studies have reported insufficient beta-lactam concentrations in critically ill patients. The optimal dosing strategy for beta-lactams in critically ill patients, particularly in septic patients, is an ongoing matter of discussion. This retrospective study aimed to evaluate the success of software-guided empiric meropenem dosing (CADDy, Calculator to Approximate Drug-Dosing in Dialysis) with subsequent routine meropenem measurements and expert clinical pharmacological interpretations. Adequate therapeutic drug exposure was defined as concentrations of 8-16 mg/L, whereas concentrations of 16-24 mg/L were defined as moderately high and concentrations >24 mg/L as potentially harmful. A total of 91 patients received meropenem as a continuous infusion (229 serum concentrations), of whom 60% achieved 8-16 mg/L, 23% achieved 16-24 mg/L, and 10% achieved unnecessarily high and potentially harmful meropenem concentrations >24 mg/L in the first 48 h using the dosing software. No patient showed concentrations <2 mg/L using the dosing software in the first 48 h. With a subsequent TDM-guided dose adjustment, therapeutic drug exposure was significantly (p ≤ 0.05) enhanced to 70%. No patient had meropenem concentrations >24 mg/L with TDM-guided dose adjustments. The combined use of dosing software and consecutive TDM promised a high rate of adequate therapeutic drug exposures of meropenem in patients with sepsis and septic shock. |
DOI: | doi:10.3390/antibiotics12071112 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
kostenfrei: Volltext: https://doi.org/10.3390/antibiotics12071112 |
| kostenfrei: Volltext: https://www.mdpi.com/2079-6382/12/7/1112 |
| DOI: https://doi.org/10.3390/antibiotics12071112 |
Datenträger: | Online-Ressource |
Sprache: | eng |
Sach-SW: | continuous infusion |
| dose approximation |
| dose optimization |
| meropenem |
| pharmacokinetics |
| therapeutic drug monitoring |
K10plus-PPN: | 1857978102 |
Verknüpfungen: | → Zeitschrift |
Software- and TDM-guided dosing of Meropenem promises high rates of target attainment in critically Ill patients / Chiriac, Ute [VerfasserIn]; 2023 (Online-Ressource)